87 related articles for article (PubMed ID: 10545794)
1. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Franssila K; Collan Y; Pyrhönen S
Oncology; 1999 Oct; 57(3):242-52. PubMed ID: 10545794
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S
Oncology; 2002; 62(3):259-68. PubMed ID: 12065874
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma.
Laprie C; Abadie J; Amardeilh MF; Net JL; Lagadic M; Delverdier M
Vet Dermatol; 2001 Jun; 12(3):139-47. PubMed ID: 11420929
[TBL] [Abstract][Full Text] [Related]
5. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin.
Talve LA; Collan YU; Ekfors TO
J Cutan Pathol; 1996 Aug; 23(4):335-43. PubMed ID: 8864921
[TBL] [Abstract][Full Text] [Related]
6. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of a histological grading system using MIB-1 for adult soft-tissue sarcoma.
Hasegawa T; Yokoyama R; Lee YH; Shimoda T; Beppu Y; Hirohashi S
Oncology; 2000; 58(1):66-74. PubMed ID: 10644943
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.
Sparrow LE; English DR; Taran JM; Heenan PJ
Am J Dermatopathol; 1998 Feb; 20(1):12-6. PubMed ID: 9504663
[TBL] [Abstract][Full Text] [Related]
9. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.
Ramsay JA; From L; Iscoe NA; Kahn HJ
J Invest Dermatol; 1995 Jul; 105(1):22-6. PubMed ID: 7615970
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness.
Moretti S; Spallanzani A; Chiarugi A; Fabiani M; Pinzi C
J Am Acad Dermatol; 2001 Feb; 44(2):188-92. PubMed ID: 11174375
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract][Full Text] [Related]
12. Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.
Pastushenko I; Van den Eynden GG; Vicente-Arregui S; Prieto-Torres L; Alvarez-Alegret R; Querol I; Dirix LY; Carapeto FJ; Vermeulen PB; Van Laere SJ
Am J Dermatopathol; 2016 May; 38(5):338-46. PubMed ID: 26909582
[TBL] [Abstract][Full Text] [Related]
13. Ki 67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters.
Soyer HP
J Cutan Pathol; 1991 Aug; 18(4):264-72. PubMed ID: 1719049
[TBL] [Abstract][Full Text] [Related]
14. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de Nictolis M; Muzzioli M; Fabris N; Romanini C; Biagini G
Gynecol Oncol; 1995 Jul; 58(1):28-33. PubMed ID: 7789886
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
16. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi.
Bergman R; Malkin L; Sabo E; Kerner H
J Am Acad Dermatol; 2001 Mar; 44(3):500-4. PubMed ID: 11209122
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of beta1 integrin expression in metastatic melanoma.
Vihinen P; Nikkola J; Vlaykova T; Hahka-Kemppinen M; Talve L; Heino J; Pyrhönen S
Melanoma Res; 2000 Jun; 10(3):243-51. PubMed ID: 10890378
[TBL] [Abstract][Full Text] [Related]
18. Vascularity and prognosis of metastatic melanoma.
Vlaykova T; Muhonen T; Hahka-Kemppinen M; Pyrhönen S; Jekunen A
Int J Cancer; 1997 Jun; 74(3):326-9. PubMed ID: 9221813
[TBL] [Abstract][Full Text] [Related]
19. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ploidy and proliferation markers in renal cell carcinoma.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Cancer; 1996 Jan; 77(1):164-71. PubMed ID: 8630925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
